Summary of demographics and AML history
| Characteristic . | Part 1 (n = 34) . | Part 2 (n = 56) . |
|---|---|---|
| Age, y | ||
| Mean | 60.6 | 55.9 |
| Standard deviation | 14.6 | 14.6 |
| Minimum-maximum | 24-82 | 22-83 |
| Sex | ||
| Male | 13 (38) | 33 (59) |
| Female | 21 (62) | 23 (41) |
| Race | ||
| American Indian or Alaskan Native | 1 (3) | 0 |
| Asian | 1 (3) | 3 (5) |
| Black or African American | 7 (21) | 7 (13) |
| White | 21 (62) | 35 (63) |
| Other | 4 (12) | 11 (20) |
| Ethnicity | ||
| Hispanic or Latino | 1 (3) | 5 (9) |
| Not Hispanic or Latino | 33 (97) | 51 (91) |
| ECOG performance status | ||
| Fully active (0) | 6 (18) | 9 (16) |
| Restricted (1) | 17 (50) | 33 (59) |
| Ambulatory (2) | 11 (32) | 14 (25) |
| AML category at diagnosis | ||
| De novo | 26 (76) | 44 (79) |
| Secondary to MDS | 4 (12) | 2 (4) |
| Secondary to chemotherapy for another cancer | 2 (6) | 4 (7) |
| Unknown | 2 (6) | 6 (11) |
| FLT3-ITD+at diagnosis | ||
| Yes | 30 (88) | 45 (80) |
| No | 2 (6) | 4 (7) |
| Unknown | 2 (6) | 7 (13) |
| Prior FLT3 inhibitor therapy | 14 (41) | 12 (21) |
| Prior allogeneic transplantation | ||
| Yes | 7 (21) | 21 (38) |
| No | 27 (79) | 34 (61) |
| Unknown | 0 | 1 (2) |
| No. of prior AML therapies | ||
| Median | 4 | 4 |
| Range | 2-12 | 1-10 |
| Characteristic . | Part 1 (n = 34) . | Part 2 (n = 56) . |
|---|---|---|
| Age, y | ||
| Mean | 60.6 | 55.9 |
| Standard deviation | 14.6 | 14.6 |
| Minimum-maximum | 24-82 | 22-83 |
| Sex | ||
| Male | 13 (38) | 33 (59) |
| Female | 21 (62) | 23 (41) |
| Race | ||
| American Indian or Alaskan Native | 1 (3) | 0 |
| Asian | 1 (3) | 3 (5) |
| Black or African American | 7 (21) | 7 (13) |
| White | 21 (62) | 35 (63) |
| Other | 4 (12) | 11 (20) |
| Ethnicity | ||
| Hispanic or Latino | 1 (3) | 5 (9) |
| Not Hispanic or Latino | 33 (97) | 51 (91) |
| ECOG performance status | ||
| Fully active (0) | 6 (18) | 9 (16) |
| Restricted (1) | 17 (50) | 33 (59) |
| Ambulatory (2) | 11 (32) | 14 (25) |
| AML category at diagnosis | ||
| De novo | 26 (76) | 44 (79) |
| Secondary to MDS | 4 (12) | 2 (4) |
| Secondary to chemotherapy for another cancer | 2 (6) | 4 (7) |
| Unknown | 2 (6) | 6 (11) |
| FLT3-ITD+at diagnosis | ||
| Yes | 30 (88) | 45 (80) |
| No | 2 (6) | 4 (7) |
| Unknown | 2 (6) | 7 (13) |
| Prior FLT3 inhibitor therapy | 14 (41) | 12 (21) |
| Prior allogeneic transplantation | ||
| Yes | 7 (21) | 21 (38) |
| No | 27 (79) | 34 (61) |
| Unknown | 0 | 1 (2) |
| No. of prior AML therapies | ||
| Median | 4 | 4 |
| Range | 2-12 | 1-10 |
Values are n (%) unless otherwise noted.
ECOG, Eastern Cooperative Oncology Group; MDS, myelodysplastic syndrome.